AVB 620

Drug Profile

AVB 620

Alternative Names: Activated cell penetrating peptide - Avelas Biosciences; Fluorescent probe - Avelas Biosciences; Fluorescent protease-activated peptide - Avelas Biosciences

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avelas BioSciences
  • Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Peptide diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 26 Sep 2017 Efficacy and adverse events data from a phase Ib trial in Breast cancer released by Avelas Biosciences
  • 05 Jul 2017 Phase-II clinical trials in Breast cancer (Diagnosis, Late-stage disease) in USA (IV) (NCT03113825)
  • 08 Dec 2016 Avelas Biosciences completes a phase Ib trial in Breast cancer (Diagnosis) in USA (NCT02391194)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top